Prothrombin Complex Concentrate
ApprovedSmall molecule
CSL BehringProthrombin Complex Concentrate is one of 79 small molecule programs targeting Liver Transplant. It is currently in Approved.
3
Indications
14
Total Trials
3
Active Trials
78
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
353 competitors in Liver Transplant
#DrugCompanyPhaseTrials
1Prothrombin Complex Concentrate
CSL BehringApproved
Cysteine Hydrochloride
NovartisPreclinical
Lenvima
EisaiPreclinical
Octreotide
Johnson & JohnsonPreclinical
Beyfortus
BeiGenePreclinical
Prostigmin
Merck & Co.Preclinical
Myfortic
NovartisPreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Myfortic
NovartisPreclinical
Cyklokapron
AAmring
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cardiac Surgery3 trials
Surgery2 trials
Intracranial Hemorrhage1 trial
Bleeding1 trial
Liberal or Adhere to Recommendations for PCC Management in Major Bleeding Following Trauma
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT06627218·650 enrolled
6 more indications
Coagulopathy1 trial
REPlaCE- Randomized Trial Evaluating the Use of Prothrombin Complex concEntrate to Improve Survival in Patients With Traumatic Coagulopathy
Unknown status·—·Phase 2·NCT03981484·280 enrolled
Neurosurgical Patients1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company